免疫检查点抑制剂：三阴性乳腺癌的新治疗线。
Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
机构信息
Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco.
Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco.
出版信息
Cancer Treat Res. 2023;188:29-62. doi: 10.1007/978-3-031-33602-7_2.
Poor prognosis is a distinctive feature of triple-negative breast cancer (TNBC). Chemotherapy has long represented the main and unique treatment for patients with TNBC. Recently, immune checkpoint inhibitors (ICIs) were investigated in several clinical trials and were approved for clinical use in TNBC patients that express programmed cell death protein-1 (PD-1) in combination with chemotherapy in the first-line setting. ICIs are also being investigated in the neoadjuvant and adjuvant settings for TNBC. This chapter aims to discuss different ICIs used to treat all TNBC stages to date.
预后不良是三阴性乳腺癌（TNBC）的一个显著特征。化疗长期以来一直是 TNBC 患者的主要且唯一的治疗方法。最近，免疫检查点抑制剂（ICIs）在几项临床试验中进行了研究，并在表达程序性死亡蛋白-1（PD-1）的 TNBC 患者中获得批准，与化疗联合用于一线治疗。ICI 也正在 TNBC 的新辅助和辅助治疗中进行研究。本章旨在讨论迄今为止用于治疗所有 TNBC 阶段的不同 ICI。
Zotero 插件